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Abstract 1 
 2 
The 2-lysophosphatidylcholine analog edelfosine induces apoptosis in highly proliferating 3 
cells, e.g. activated immune cells. We examined mechanisms of action of edelfosine on 4 
immune functions in experimental autoimmune encephalomyelitis, a well-accepted animal 5 
model for multiple sclerosis. We observed activated caspase-3 expression in lymphoid organs 6 
and the central nervous system, however, edelfosine did not induce global apoptosis. 7 
Edelfosine improved the disease course and led to reduced frequencies of CD4+ T cells 8 
infiltrating into the central nervous system. Our data suggest edelfosine as an interesting 9 
treatment candidate for multiple sclerosis. 10 
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1. Introduction 1 
 2 
Apoptotic cell death is an elementary cellular response and involves the sequential activation 3 
of caspases. The stress-inducible, intrinsic apoptotic pathway involves cytochrome c release 4 
from mitochondria (Liu et al., 1996). The extrinsic pathway is induced by pro-apoptotic and 5 
pro-inflammatory cytokines, e.g. FasL, TRAIL and TNF-α, respectively, which induce the 6 
intracellular formation of specific death-inducing signaling complexes (DISCs) after binding 7 
to death domain receptors (Micheau and Tschopp, 2003; Scaffidi et al., 1999). Downstream 8 
caspases, e.g. caspase-3, are cleaved to execute cell death. Importantly, elimination of cells 9 
via apoptosis does not lead to inflammation or immune activation. Therefore, approaches to 10 
induce apoptosis in deregulated, e.g. self-reactive immune cells have been considered to treat 11 
autoimmune diseases, for instance multiple sclerosis (MS).  12 
Many potentially pathogenic factors and disease mechanisms have been examined in animal 13 
models, particularly in experimental autoimmune encephalomyelitis (EAE) (Raine et al., 14 
1980), and both animal and human studies point to a central role for autoreactive CD4+ T cells 15 
in MS pathology (Sospedra and Martin, 2005). CD4+ T cells are present in central nervous 16 
system (CNS) and cerebrospinal fluid (CSF) cellular infiltrates in both MS and EAE (Martin 17 
et al., 1990; Ota et al., 1990; Pettinelli and McFarlin, 1981; Richert et al., 1983). Further, 18 
albeit indirect evidence for their role stems from the observation that a large fraction of the 19 
genetic risk of MS is conferred by HLA-class II alleles of the HLA-DR15 haplotype (Hillert 20 
and Olerup, 1993; Jersild et al., 1973). Recently published large genome-wide association 21 
studies show over 130 single nucleotide polymorphisms besides HLA-DR as risk alleles for 22 
MS (Beecham et al., 2013; Sawcer et al., 2011), and interestingly many of these are involved 23 
in T cell activation and function (Lundmark et al., 2007; McElroy and Oksenberg, 2008).  24 
Following priming with (auto)antigens to potentially autoreactive CD4+ T cells in the 25 
periphery, activated CD4+ T cells transmigrate across the blood brain barrier (BBB) and the 26 
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blood CSF barrier (Cannella and Raine, 1995). Next, T cells are locally reactivated by antigen 1 
presenting cells within the CNS (Flügel et al., 2001). Subsequently, a number of immune cells 2 
including those of the innate (neutrophils, macrophages, dendritic cells (DCs), natural killer 3 
(NK) cells) and adaptive (CD4+ and CD8+ T cells, B cells) immune system (Franciotta et al., 4 
2008; Hauser et al., 2008; Lucchinetti et al., 1996) are recruited and form focal inflammatory 5 
lesions (Simpson et al., 1998). Immunodominant peptides of myelin proteins, e.g. myelin 6 
oligodendrocyte glycoprotein (MOG) peptide MOG(35-55), are used to induce chronic EAE in 7 
C57BL/6 mice, whereas relapsing-remitting EAE (RR-EAE) in SJL mice follows the 8 
injection of proteolipid protein (PLP) peptide PLP(139-154). 9 
The synthetic 2-lysophosphatidylcholine (LPC) analog edelfosine (1-O-octadecyl-2-O-10 
methyl-rac-glycero-3-phosphocholine, ET-18-OCH3) was found to induce selective apoptosis 11 
in leukemic cells (Diomede et al., 1993; Mollinedo et al., 1993). In contrast to other cytotoxic 12 
drugs edelfosine does not target the DNA and it does not directly interfere with the formation 13 
and function of the cellular replication machinery. Edelfosine binds to Fas/CD95 in a lipid 14 
raft-mediated process thereby exerting its cytotoxic activity (Gajate and Mollinedo, 2001; van 15 
der Luit et al., 2002). Detailed mechanistic studies have demonstrated that edelfosine-treated 16 
Jurkat leukemic T cells undergo apoptosis following recruitment of DISCs into lipid rafts 17 
(Gajate et al., 2009). Edelfosine accumulates in the inner leaflet of the plasma membrane in 18 
lipid rafts, which in turn induces the clustering of rafts and the recruitment of Fas into rafts 19 
with subsequent translocation of Fas, FADD and caspase-8 into rafts, DISC formation and 20 
activation of caspase-8 to induce apoptosis in the absence of FasL. Normal, resting cells are 21 
not able to take up significant amounts of edelfosine (Gajate et al., 2000). Additionally, 22 
edelfosine may accumulate in lipid rafts within the plasma membrane followed by 23 
endocytosis and translocation to the intracellular location of the CTP:phosphocholine 24 
cytidylyltransferase (CCT), the endoplasmic reticulum (ER) (Clement and Kent, 1999; van 25 
der Luit et al., 2007, 2002). Here, edelfosine may inhibit the biosynthesis of 26 
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phosphatidylcholine (PC) leading to mitotic arrest and apoptosis (Boggs et al., 1995; Van Der 1 
Luit et al., 2003). This effect was found in exponentially growing cells, which require high 2 
amounts of PC, while normal quiescent cells were not affected (van der Sanden et al., 2004; 3 
Zerp et al., 2008). The relative contribution of each mechanism may depend on the cell type 4 
and the concentration of edelfosine (Mollinedo et al., 1997; Tsutsumi et al., 1998; Zoeller et 5 
al., 1995). Thus, alkyl lysophospholipids like edelfosine may affect several cellular processes, 6 
probably with cell type-dependent emphasis but with the joint outcome of apoptosis 7 
induction. 8 
Due to its immunomodulatory properties and its oral availability edelfosine had already been 9 
examined as a treatment for MS in the past (Klein-Franke and Munder, 1992; Munder and 10 
Westphal, 1990). Although not performed according to today’s standards exploratory clinical 11 
trials demonstrated the drug’s excellent safety profile. Parallel EAE studies, mostly with rats, 12 
but also with mice described a beneficial effect of edelfosine treatment on clinical outcome 13 
(Baker et al., 1991; Chabannes et al., 1992; Klein-Franke and Munder, 1992; Kovarik et al., 14 
1995). So far, however, functional investigations on edelfosine-induced modifications of 15 
cellular responses in the context of EAE are limited. We therefore wanted to reassess and 16 
expand prior work in the EAE model to examine in more detail the mechanism/s of action of 17 
edelfosine as a potential treatment in autoimmune diseases, for instance MS. 18 
 19 
 20 
2. Materials and Methods 21 
 22 
2.1 Ethics statement 23 
All animal experiments were performed in accordance with the guidelines of the local 24 
authorities (Behörde für Soziales, Gesundheit und Verbraucherschutz Hamburg; G22/08). 25 
 26 
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2.2 Preparation of edefosine 1 
For in vivo applications, edelfosine (Medmark, Oberhaching, Germany) was dissolved in aqua 2 
ad injectabilia and diluted with PBS (PAA, Pasching, Austria). The diluted edelfosine was 3 
stored at -20°C and thawed on the day of application. The injected edelfosine dose per mouse 4 
was 1 mg/kg, 10 mg/kg, 15 mg/kg and 25 mg/kg edelfosine. Edelfosine was applied by 5 
intraperitoneal injection or by gavage. 6 
 7 
2.3 Mice 8 
C57BL/6J mice were purchased from the Jackson Laboratory and bred by the animal facility 9 
of the University Medical Center Hamburg Eppendorf. SJL/JHanTMHsd mice were purchased 10 
from Harlan Laboratories, Indianapolis, IN, USA. 11 
 12 
2.4 Induction of EAE 13 
For EAE experiments C57BL/6 mice or SJL mice were housed in “individually ventilated 14 
cages (IVC)”-racks at least one week prior to the active induction of EAE. On the day of 15 
immunization mice were injected subcutaneously at two sites of the flanks with 200 µg of 16 
MOG(35-55) (NeoMPS, San Diego, CA, USA) or 75 µg/ml of PLP(139-151) (NeoMPS) peptide in 17 
incomplete Freund’s adjuvant (BD Difco Diagnostics, Sparks, MD, USA) supplemented with 18 
4 mg/ml Mycobacterium tuberculosis H37 Ra (BD Difco). C57BL/6 mice were injected 19 
intravenously with 300 ng of pertussis toxin (Calbiochem Merck, Darmstadt, Germany) on 20 
the day of immunization and 48 h later. SJL mice received a single dose of 200 ng pertussis 21 
toxin on the day of immunization. Body weight and clinical score were monitored on a 0 to 5 22 
scale with classifications of disease severity: 0 = healthy, 1 = limp tail, 2 = ataxia and/or 23 
paresis of hind limbs, 3 = paraplegia, 4 = paraplegia with forelimb weakness, 5 = moribund or 24 
dead.  25 
 26 
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2.5 Preparation of cells from secondary lymphoid organs and CNS of mice 1 
For preparation of lymph nodes and spleens mice were sacrificed at day 9 after immunization. 2 
Single cell suspensions were prepared by mincing the tissue and pushing it through a 40 µm 3 
cell sieve. Cells derived from the spleen were resuspended in 5 ml red blood cell lysis buffer 4 
(0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA in ddH2O) and incubated on ice for 7 5 
min. Cells were resuspended in FACS buffer (0.1% BSA, 0.02% NaN3 in PBS) or PBS + 1% 6 
FCS if the preparation was followed by recall experiments. At the acute phase of EAE mice 7 
were perfused transcardially with 50 ml PBS supplemented with 1% FCS to prepare the CNS. 8 
Dissected brain and spinal cord were digested for 60 min at 37°C by addition of 1 mg/ml 9 
collagenase I and 0.1 mg/ml DNase I (both from Roche, Penzberg, Germany) in D-MEM 10 
(Gibco, Carlsbad, CA, USA). The cell suspension was passed through a 40 µm cell strainer 11 
and centrifuged (250xg, 10 min, 4°C). Cells were separated from myelin and neurons by 12 
Percoll (GE Healthcare, Chalfont St. Giles, UK)-gradient centrifugation (30%/78%). CNS-13 
infiltrating cells and microglia were collected from the interface. Cells were resuspended in 14 
FACS buffer, centrifuged (550xg, 10 min, 4°C) and washed two additional times (250xg, 10 15 
min, 4°C). 16 
 17 
2.6 Cell culture experiments 18 
To determine T cell proliferation by [methyl-3H]-thymidine incorporation, spleen- and lymph 19 
node-derived cells were seeded in 96-well plates (Greiner Bio-One, Frickenhausen, Germany) 20 
at 2x105 cells/well. Murine cells were cultured in 200 µl of complete mouse medium (50 µM 21 
β-mercaptoethanol, 10% FCS in RPMI1640 medium, GlutaMAXTM (Gibco)) supplemented 22 
with the disease-relevant peptide PLP(139-151), a polyclonal anti-CD3 antibody (145-2C11, 23 
from eBioscience, San Diego, CA, USA) or mitogenic Concanavalin A (Con A, from Sigma-24 
Aldrich, St. Louis, MO, USA).  25 
 26 
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2.7 Immunohistochemistry 1 
Mice were transcardially perfused with cold PBS followed by 4% cold PFA (AppliChem, 2 
Darmstadt, Germany) in phosphate buffer. Preparation of brain, spinal cord and optic nerves 3 
was followed by post-fixation of the tissue in 4% PFA in phosphate buffer (30 min, 4°C). The 4 
tissue was impregnated 2-3 days in 30% sucrose in PBS for cryoprotection. Cervical, thoracic 5 
and lumbar spinal cord as well as cerebellum and forebrain were separated. The tissue was 6 
embedded in Tissue Freezing Medium (Jung, Leica Biosystems, Nussloch, Germany) and 7 
frozen in isopentane (Carl Roth, Karlsruhe, Germany). Tissue was stored at -80°C. 12-14 µm 8 
slices were generated using a cryostat and mounted on glass microslides (Superfrost/Plus 9 
from Karl Hecht, Sondheim, Germany). For quantification of Neuronal Nuclei (NeuN)-10 
expressing neuronal cells within the cervical spinal cord 14 µm cryosections were rinsed 3x 11 
with PBS and incubated for 2 h at RT in blocking solution (0.1% Triton X 100 (Carl Roth), 12 
10% normal donkey serum (Chemicon, Billerica, MA, USA) in PBS). Subsequently, primary 13 
anti-NeuN antibody (A60, Millipore, Billerica, MA, USA) was added, and the sections were 14 
incubated at 4°C over night. The tissue was rinsed 3x with PBS and incubated with 15 
DyLight488-labeled secondary antibody (Jackson ImmunoResearch, Newmarket, UK). Anti-16 
NeuN antibody was diluted 1:100 in PBS, the secondary antibody was diluted 1:400 in PBS. 17 
For each mouse, six cervical spinal cord sections were selected and two adjacent photographs 18 
per ventral horn were made. Quantification was carried out by detection of NeuN+ neurons 19 
within the ventral horn including the lower motor neurons. Cervical spinal cord sections from 20 
age-matched, not-immunized SJL control mice were used to rank EAE-induced neuronal loss 21 
and edelfosine-mediated treatment effects. Images were acquired using a Axiovert 40 inverted 22 
microscope (Carl Zeiss, Jena, Germany) and analyzed with AxioVision AxioVs40 V 4.6.3.0 23 
software (Zeiss). Photographs were taken with 20x magnification. NeuN+ cells were counted 24 
and the average number of neurons per section was calculated. 25 
 26 
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2.8 [methyl-3H]-thymidine-incorporation assay 1 
T cells were derived from lymph nodes and spleens of SJL mice that were immunized as 2 
previously described. T cell proliferation was determined by the incorporation of [methyl-3H]-3 
thymidine (Hartmann Analytic, Braunschweig, Germany) after 72 h of incubation. 16 h 4 
before harvesting the cells, 1 µCi [methyl-3H]-thymidine was added to each well. For 5 
quantification of beta particle emission the cells were harvested, washed and analyzed by 6 
using a beta counter (Wallac, Waltham, MA, USA). The stimulation index (SI) is calculated 7 
by dividing the mean counts per minute (cpm) of stimulated cells by cpm of respective 8 
unstimulated controls.  9 
 10 
2.9 Flow cytometry 11 
For the analysis of intracellular cytokines cells were incubated for 4 h in complete mouse 12 
medium supplemented with 100 ng/ml PMA and 1 µg/ml ionomycin (both from Sigma-13 
Aldrich). After 1 h 10 µg/ml Brefeldin A (BioLegend, San Diego, CA, USA) was added. For 14 
Fc-receptor blocking cells were incubated in FACS buffer supplemented with anti-15 
CD16/CD32 antibody (93, eBioscience). CNS-infiltrating leukocytes were quantified using 16 
BD Trucount Absolute Counting Tubes (BD Biosciences, San Jose, CA, USA) and anti-CD45 17 
antibody. For intracellular staining of cytokines, but also of activated caspase-3, IC fixation 18 
buffer and permeabilization buffer (eBioscience) were used. Staining for Foxp3 was 19 
performed according to the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). For 20 
exclusion of dead cells from the preparation of CNS-infiltrating immune cells, the 21 
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Carlsbad, CA, USA) was used. 22 
The following antibodies were used to perform analysis by flow cytometry: anti-CD3-23 
PacificBlue (500A2), anti-NK1.1-PE-Cy7 (PK136) and anti-caspase-3-PE (C92-605) from 24 
BD Pharmingen (San Diego, CA, USA), anti-CD3-PerCP-Cy5.5 (145-2C11), anti-CD4-FITC 25 
(GK1.5), anti-CD8a-PE-Cy7 (53-6.7), anti-CD45-APC-Cy7 (30-F11) from BioLegend, as 26 
10 
 
well as anti-CD4-APC-eFluor780 (RM4-5), anti-CD4-eFluor450, anti-CD4-PE (GK1.5), anti-1 
CD8a-eFluor450 (53-6.7), anti-CD11b-APC (M1/70), anti-CD11b-FITC (M1/70), anti-2 
CD11c-APC (N418), anti-CD11c-PE-Cy7 (N418), anti-CD25-APC (PC61.5), anti-CD44-3 
APC (IM7), anti-CD45-PE-Cy7 (30-F11), anti-CD45R(B220)-PE-Cy5.5 (RA3-6B2) anti-4 
CD62L-PE-Cy7 (MEL-14), anti-CD69-FITC (H1.2F3), anti-IFN-γ-PE (XMG1.2), anti-IL-5 
17A-Alexa647 (17B7), anti-Ly-6G-FITC (RB6-8C5), anti-Ly-6G-PE (RB6-8C5) and anti-6 
NK1.1-PE (PK136), all from eBioscience. Data was acquired on an LSRII flow cytometer 7 
(BD Biosciences, San Jose, CA, USA) and analyzed with BD FACSDiva and FlowJo (Tree 8 
Star, Ashland, OR, USA) software. 9 
 10 
2.10 Statistical analysis 11 
EAE disease courses were analyzed by two-way ANOVA and Bonferroni multiple testing 12 
correction (post-hoc analysis) using Prism 5.02 software (GraphPad Software, La Jolla, CA, 13 
USA). In graphs representing the EAE disease courses treatment effects were indicated by 14 
asterisks. Significant differences between groups were described in respective figure legends 15 
after Bonferroni post-hoc analysis. Cumulative disease scores and neuronal quantification by 16 
immunohistochemistry were analyzed by 1-way ANOVA followed by Bonferroni post-hoc 17 
test with asterisks indicative of significant differences between groups. Moreover, data 18 
generated by flow cytometry for leukocyte subsets derived from EAE-induced mice were 19 
evaluated by Bonferroni post-hoc analysis after 1-way ANOVA. With regard to lymph nodes 20 
and spleen-derived subsets, frequencies were normalized and expressed as fold-changes in 21 
order to allow merging of two independent experiments. Ex vivo proliferation assays of 22 
murine lymph node cells were analyzed by 1-way ANOVA and Bonferroni post-hoc analysis, 23 
whereas results of proliferation assays of spleen-derived cells were tested by non-parametric 24 
Kruskal-Wallis test followed by Dunns post-hoc analysis.  25 
 26 
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 1 
3. Results 2 
 3 
3.1 Edelfosine treatment improves clinical symptoms in the EAE mouse model 4 
 5 
In a first dose finding study we examined edelfosine in the chronic, MOG peptide-induced 6 
EAE model in C57BL/6 mice (Fig. 1A). From the day of immunization (day 0) mice were 7 
administered with equal volumes of edelfosine or PBS by gavage on a daily basis. The PBS-8 
treated control cohort developed first signs of EAE at day 12 after immunization reaching 9 
maximum EAE score at day 18. This acute phase of disease was shifted to later days if mice 10 
were treated with edelfosine. In contrast to higher doses the treatment of mice with 10 mg/kg 11 
edelfosine did not lead to apparent side effects, e.g. tremor, inactivity, and slowed motion, but 12 
resulted in a reduced EAE score. Administration of edelfosine led to a significant 13 
amelioration of EAE when comparing PBS-treated controls and mice treated with 10 mg/kg 14 
edelfosine. We therefore continued with 10 mg/kg as effective edelfosine concentration.  15 
In a subsequent preventive approach we studied the effects of edelfosine on RR-EAE disease 16 
course in SJL mice. SJL mice were immunized with the PLP(139-151) peptide (day 0). Notably, 17 
the treatment of mice with edelfosine from day 5 every other day by i.p. injection did not 18 
result in significant differences between cohorts regarding treatment effects in the course of 19 
EAE (Fig. 1B) and regarding cumulative disease scores (Fig. 1D) despite a trend to improved 20 
disease scores. To investigate the therapeutic effectiveness of edelfosine on EAE, SJL mice 21 
were immunized and disease scores were monitored. Mice showed first distinct and evenly 22 
distributed signs of EAE across groups at day 11. Treatment with PBS, 1 mg/kg edelfosine, or 23 
10 mg/kg edelfosine was started at this day and continued until day 45 (Fig. 1C). Clinical 24 
scores upon edelfosine treatment were reduced, however, the treatment effect did not reach 25 
statistical significance despite a clear tendency towards reduced cumulative disease scores in 26 
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edelfosine-treated cohorts (a significant treatment effect with significant differences between 1 
PBS-treated and 10 mg/kg edelfosine-treated groups was detectable for the therapeutic 2 
treatment setting if EAE scores were analyzed until day 20), summarized in Fig. 1E. 3 
However, the preventive edelfosine treatment of SJL mice was effective when started at day 4 
0. Immediately after EAE induction PBS, 1 mg/kg edelfosine, or 10 mg/kg edelfosine was 5 
administered and repeated on a daily basis by i.p. injection. The progression of disease course 6 
was monitored until day 40 (Fig. 2A). A significant treatment effect was found in this 7 
preventive setting. Interestingly, differences emerged at the first disease bout from day 12 to 8 
14 as well as at the first EAE relapse from day 28 to 33. A significant treatment effect was 9 
also detected when the cumulative disease scores of the three cohorts were analyzed (Fig. 10 
2B). Differences in post-hoc analysis were found for the comparison of PBS-treated controls 11 
to 10 mg/kg edelfosine-treated mice. 12 
 13 
3.2 Preventive edelfosine treatment increases activated caspase-3 expression in the 14 
preclinical phase of RR-EAE 15 
 16 
For a detailed analysis of the impact of edelfosine on different immunological parameters 17 
immunized SJL mice received PBS, 1 mg/kg edelfosine, or 10 mg/kg edelfosine by i.p. 18 
injection from the day of immunization (day 0) on a daily basis until day 9. There were no 19 
differences in absolute cell numbers in spleens as well as draining lymph nodes during the 20 
preventive treatment (data not shown). Furthermore, neither immune cell subset derived from 21 
spleens nor subsets derived from lymph nodes displayed any edelfosine treatment-associated 22 
changes in frequencies compared to PBS-treated controls (CD3+ T cells, B220+ B cells, 23 
CD11b+CD11c- macrophages, Ly-6G+CD11b+ neutrophils, CD11b-CD11c+B220- myeloid 24 
DCs, NK1.1+CD45+CD11b+CD3- NK cells, CD11b-CD11clowB220+Ly-6Glow plasmacytoid 25 
DCs, data not shown). The gating strategy is shown in Supplementary Fig. 1. Further, no 26 
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differences in global CD4+ and CD8+ T cells were observed (Fig. 3A and -B), while naïve 1 
CD4+CD62LhighCD44low T cells increased in lymph nodes upon edelfosine treatment (Fig. 2 
3C). No differences were seen between frequencies of CD4+CD69+ or CD4+CD25+ T cells 3 
isolated from spleens and lymph nodes in either group or for the respective CD8+ T cell 4 
populations (data not shown). Thus, edelfosine treatment did not influence frequencies of T 5 
cells in the periphery, which express strong activation signals. As an additional CD4+ T cell 6 
subset CD4+CD25+Foxp3+ natural regulatory T cells (nTregs) were identified in spleens and 7 
lymph nodes of EAE-induced mice by gating on CD4+CD25+ populations excluding CD69+ 8 
events. The comparison of nTreg frequencies from PBS-treated and edelfosine-treated cohorts 9 
in either spleens or lymph nodes did not indicate treatment-dependent changes (data not 10 
shown). The treatment of EAE-induced mice with edelfosine was not found to have an impact 11 
on IFN-γ or IL-17-producing CD4+ as well as CD8+ lymphocyte subset frequencies in the 12 
spleen or lymph nodes compared to controls (data not shown). Hence, it does not appear that 13 
edelfosine leads to global perturbations of the peripheral immune system. 14 
Since it had previously been demonstrated that elimination of T cells from the brain in the 15 
EAE model involves apoptosis (Schmied et al., 1993), and since this is the presumed 16 
mechanism of action of edelfosine, we wanted to examine this aspect by caspase-3 activation 17 
as an early step of apoptosis upon edelfosine treatment. Therefore, CD4+ and CD8+ T cells 18 
prepared from spleens and lymph nodes of EAE-induced mice that were treated with PBS or 19 
edelfosine were stained for caspase-3 activation (Fig. 4A and -B). As edelfosine is described 20 
as acting primarily on proliferating cells, CD69 was used to specifically determine activated T 21 
cells. In spleens the treatment of EAE-induced mice with 10 mg/kg edelfosine led to a 22 
significant increase in frequencies of CD4+ (1.70-fold) and CD8+ (1.99-fold) T cells with 23 
activated caspase-3 compared to PBS-treated, immunized mice (Fig. 4C). 10 mg/kg 24 
edelfosine also resulted in a 1.59-fold increase in frequencies of CD4+ T cells with activated 25 
caspase-3 compared to 1 mg/kg edelfosine. Additionally, activated caspase-3-expressing 26 
14 
 
CD69+CD8+ T cell frequencies were elevated in spleens after 10 mg/kg edelfosine treatment 1 
(2.04-fold compared to PBS, 1.95-fold compared to 1 mg/kg edelfosine).  2 
 3 
3.3 Edelfosine treatment does not compromise the proliferative capacity of T cells in RR-4 
EAE 5 
 6 
Spleen and lymph node cells of edelfosine-treated mice retained their proliferative capacity as 7 
shown in ex vivo proliferation experiments. Of interest, ex vivo activation with PLP(139-151) 8 
appears to indicate an edelfosine dose-dependent effect on proliferation in vivo (Fig. 5A). 9 
Increased SIs were found at higher doses of edelfosine (Fig. 5B). This phenomenon is caused 10 
by the greater reduction of background proliferation (in the absence of antigenic stimulus in 11 
vitro) as a result of edelfosine treatment of mice (Fig. 5A and -B). 12 
 13 
3.4 Edelfosine treatment reduces CNS-infiltrating T cell frequencies and leads to 14 
expression of activated caspase-3  15 
 16 
The acute phase of EAE is clinically apparent through maximal impairment of motor 17 
function. Pathologically, this period is characterized by a marked infiltration of immune cells 18 
from the periphery into the CNS. In this set of experiments SJL mice were immunized with 19 
PLP(139-151) to induce EAE. Mice were either treated with PBS, 1 mg/kg edelfosine, or 10 20 
mg/kg edelfosine from the day of immunization on a daily basis. PBS-treated mice displayed 21 
a maximum mean EAE score of 2.67 ± 0.51 at day 14 after immunization (Supplementary 22 
Fig. 2A). By contrast, mice treated with 1 mg/kg or 10 mg/kg edelfosine showed a 23 
considerably lower clinical score (1.63 ± 0.42 and 0.13 ± 0.13, respectively). At day 15 spinal 24 
cords and brains were prepared to analyze cellular infiltration of the CNS by flow cytometry 25 
(Supplementary Fig. 2B and 2C, Supplementary Fig. 3). No significant differences of absolute 26 
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cell numbers in the CNS were detected between PBS-treated mice and at both doses of 1 
edelfosine (Supplementary Fig. 2B). 10 mg/kg edelfosine resulted in reduced frequencies (-2 
1.71-fold) of CD3+ T cells in the CNS (Supplementary Fig. 2D) and at the same time 3 
increased frequencies (6.46-fold) of neutrophils compared to PBS controls. CD4+ T cell 4 
frequencies were reduced at 10 mg/kg edelfosine in comparison to 1 mg/kg edelfosine or 5 
control (-1.17-fold) (Fig. 6). In contrast, no differences were determined for CD8+ T cells 6 
(Fig. 6). Compared to PBS edelfosine did not alter the frequency of CNS-infiltrating nTregs 7 
(Fig. 6) or IFN-γ-producing CD4+ T cells, while IFN-γ-producing CD8+ T cells were reduced 8 
(Fig. 7). Edelfosine led to a significant treatment effect in view of IL-17-producing CD4+ T 9 
cells, but no differences could be detected between groups after post-hoc analysis (Fig. 7). 10 
Finally, the impact of edelfosine treatment on apoptosis induction, i.e. caspase-3 activation, in 11 
CNS-infiltrating T lymphocyte subsets was investigated (Fig. 8), and a clear increase of 12 
caspase-3-expressing CD4+ T cells (4.63-fold) was detected at 10 mg/kg edelfosine compared 13 
to PBS-treated controls. No differences were detected for caspase-3 activation in CD8+ T 14 
cells.  15 
 16 
3.5 Preventive edelfosine treatment reduces neuronal loss in acute RR-EAE 17 
 18 
To detect and quantify the damage of neurons within the cervical spinal cord of EAE-affected 19 
SJL mice during the acute disease phase, tissue sections were prepared for 20 
immunohistochemistry. Sections were stained with antibodies against the neuron-specific 21 
nuclear protein NeuN (Fig. 9). Compared to controls a significant decrease in NeuN+ neurons 22 
was detected in EAE-induced, PBS-treated mice. Neuronal loss could be reduced markedly by 23 
treatment with 1 mg/kg or 10 mg/kg edelfosine.  24 
 25 
 26 
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4. Discussion  1 
 2 
The main findings of our study are the clinical amelioration of RR-EAE by systemic 3 
edelfosine treatment and, at the level of its mechanism, the increase of apoptosis-prone, 4 
activated caspase-3-expressing CD4+ T cells within the CNS of EAE-induced mice. 5 
Additionally, proliferative T cell responses upon recall stimulations were not impaired, and 6 
neuronal damage was decreased upon treatment. Our results, therefore, translate in vitro 7 
generated mechanistic knowledge about edelfosine into the in vivo settings.  8 
10 mg/kg edelfosine was identified to be effective in ameliorating chronic-progressive EAE 9 
without causing side effects after preventive, oral administration. Additionally, EAE 10 
incidences were reduced upon edelfosine treatment confirming observations in Biozzi AB/H 11 
mice (Baker et al., 1991). In accordance with these previous EAE trials in Biozzi AB/H mice, 12 
10 mg/kg edelfosine treatment resulted in delayed onset of EAE. The beneficial effect of 10 13 
mg/kg edelfosine was subsequently validated in the relapsing-remitting EAE model in SJL 14 
mice. As experiments by Klein-Franke and Munder pointed to the effectiveness of treatment 15 
initiation from day 5 after immunization, SJL mice received edelfosine from day 5 in a second 16 
EAE experiment (Klein-Franke and Munder, 1992). Additionally, dose rates were limited by 17 
edelfosine treatment only every other day. Interestingly, pharmacokinetic studies in rats 18 
reported a rapid uptake and distribution of a liposomal formulation of an edelfosine L-isomer 19 
into tissues (time to reach highest concentrations: 0.25 to 8 h, half-lives were 13.1 h in blood 20 
and 14 h in spleens) (Bhamra et al., 2003). Furthermore, approximately 96% of edelfosine 21 
was absorbed in the first 24 hours after oral treatment of rats (Kötting et al., 1992). These and 22 
our data denote that edelfosine given every 48 h may not be suitable for maintaining a local 23 
concentration necessary to interfere with the priming of autoreactive immune cells in EAE 24 
and that intervals need to be reduced to balance clearance of edelfosine from peripheral 25 
lymphoid organs. In the preventive setting, daily treatment was adequate, probably by 26 
17 
 
sustaining edelfosine concentrations in peripheral lymphoid organs, which were effective to 1 
interfere with immune cell functions. These results suggest that edelfosine acts not only via 2 
modulation of T cell priming for EAE induction but also on induction of relapses.  3 
LPC and its synthetic analogs were initially described to enhance the phagocytic activity of 4 
macrophages (Burdzy et al., 1964; Munder et al., 1969, 1966). Therefore they were assigned 5 
an immunomodulatory role in defense mechanisms of the immune system. Since MS but also 6 
EAE are mediated by myelin-specific encephalitogenic T cells (Coles et al., 1999; Martin et 7 
al., 1992; Wekerle et al., 1986; Zamvil and Steinman, 1990), treatment effects on T cell 8 
priming in secondary lymphoid tissues were determined. Edelfosine does not act by 9 
indiscriminately eliminating cells in secondary lymphoid organs that are indispensable for 10 
priming and triggering antigen-specific immunity, i.e. edelfosine does not lead to major 11 
perturbations or loss of peripheral immune cells. Importantly, edelfosine treatment did not 12 
induce the ablation of nTregs from peripheral lymphoid organs. Tregs are thought to be 13 
involved in preventing the development of autoimmune diseases, and changes in number and 14 
function were also reported in MS (Haas et al., 2005; Viglietta et al., 2004) and EAE 15 
(McGeachy et al., 2005; Yu et al., 2005; Zhang, 2004). The frequencies of nTregs after 16 
repeated edelfosine treatment were not altered indicating that it does not affect nTreg-17 
mediated peripheral tolerance mechanisms. To confirm the previously shown apoptosis 18 
induction by edelfosine the frequencies of caspase-3-activated CD4+ and CD8+ T cells were 19 
evaluated. The ex vivo analysis of peripheral T cells from edelfosine-treated, EAE-induced 20 
mice demonstrated increased frequencies of apoptosis-prone T cells. 21 
To further delineate the influence of daily edelfosine treatment on the functional properties of 22 
spleen and lymph node-derived T cells, cells were used in ex vivo restimulation experiments. 23 
Repetitive edelfosine treatment of mice was not found to interfere with the capacity of 24 
lymphocytes to proliferate and to respond to inflammatory cues independent of the stimulus 25 
(mitogenic, polyclonal or antigen-specific). Upon each of the stimuli no significant change in 26 
18 
 
proliferation was observed by daily edelfosine treatment confirming that edelfosine does not 1 
compromise the proliferative potential of T cells. These findings are of practical and 2 
translational relevance, since some of the approved immunomodulatory drugs for MS, e.g. 3 
mitoxantrone and alemtuzumab to name two approved drugs, eradicate a wide spectrum of 4 
immune cells or broadly inhibit immune function. Such therapies carry the risk of various side 5 
effects, among which the increase in susceptibility to infections.  6 
In EAE, impairment of motor function is maximal during acute disease, and edelfosine 7 
ameliorated the functional deficits as shown by reduced EAE scores. One curious observation 8 
is the increase of neutrophils in the CNS of mice receiving 10 mg/kg edelfosine. While we 9 
can only speculate on the causes of this finding, edelfosine crosses the BBB (Arnold et al., 10 
1978; Bhamra et al., 2003; Estella-Hermoso de Mendoza et al., 2009). Drug concentrations 11 
that are achieved by administration of 10 mg/kg edelfosine treatment may be sufficient to 12 
induce activation in neutrophils. Neutrophils can be activated in vitro by platelet activating 13 
factor (PAF) (Read et al., 1993), and interestingly, PAF is a natural analogue of edelfosine. 14 
PAF has been involved in inflammatory processes like neutrophil chemotaxis (Chignard et al., 15 
1979; O’Flaherty et al., 1981). Human neutrophils showed increased cytosolic free Ca2+ 16 
concentration mediated by edelfosine binding to PAF-R, but the affinity was 5000-fold lower 17 
compared to PAF (Alonso et al., 1997). Mature peripheral blood neutrophils were not 18 
susceptible to edelfosine-induced apoptosis (Mollinedo et al., 1997). Thus, edelfosine may not 19 
be able to induce apoptosis but rather to activate neutrophils due to molecular similarities with 20 
its physiological counterpart PAF. EAE is mainly mediated by CD4+ T cells, and the 21 
specificity of autoreactive T cells for distinct myelin peptides has been studied in detail 22 
(McRae and Miller, 1994; McRae et al., 1995; Pettinelli and McFarlin, 1981). Accordingly, 23 
our results emphasize that edelfosine affects the disease-relevant cell population with relative 24 
specificity. CD8+ T cells in EAE may have regulatory functions (Friese and Fugger, 2005; 25 
Linker et al., 2005; Zeine and Owens, 1993). However, these cells also produce IFN-γ and 26 
19 
 
potentially serve as an early source of IFN-γ driving Th1-cell differentiation (Das et al., 1 
2011). Treatment with edelfosine led to reduced frequencies of IFN-γ-producing CD8+ T 2 
cells. In lymphocyte infiltrates of the CNS increased frequencies of CD4+ T cells that 3 
expressed activated caspase-3 after edelfosine treatment were found. These data indicate that 4 
either edelfosine is able to induce apoptosis in T cells that have infiltrated the CNS of EAE 5 
mice or that the treatment is sufficient to induce apoptosis in T cells in the periphery, which 6 
may not prevent those cells from infiltrating the CNS but still leads to disease amelioration. 7 
As a summary result edelfosine treatment prevents neuronal loss and ameliorates EAE. 8 
Accordingly, immunohistochemical data correlated with disease scores.  9 
Recently, we were able to show that edelfosine also inhibits homeostatic proliferation of 10 
human T cells, i.e. proliferation in the absence of an antigenic stimulus (Abramowski et al., 11 
2014). While we did not examine this aspect in detail in the present study, the above 12 
observation of higher stimulation indices in antigen-specific proliferation studies due to 13 
reduced background proliferation (see Fig. 5B) indicates that inhibition of homeostatic 14 
proliferation also applies to murine cells. Further analyses in human T- and B cells 15 
demonstrated novel mechanisms of action of edelfosine including the downmodulation of 16 
MHC-class II molecules and the induction of type I IFN-associated genes (Abramowski et al., 17 
2014). Here, we complemented these in vitro data with human cells and show the 18 
effectiveness of edelfosine treatment in EAE as well as the in vivo induction of apoptosis in 19 
disease-relevant T cell subsets. Our results underscore the potential of edelfosine to treat 20 
autoimmune diseases including MS. 21 
 22 
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Figure Captions 1 
 2 
Figure 1. EAE disease course in C57BL/6 and SJL mice was dependent on edelfosine 3 
treatment. (A) Whereas PBS-treated C57BL/6 mice developed the classical chronic-4 
progressive EAE course, mice treated with edelfosine appeared to be impacted in their EAE 5 
development but also in their physical presentation due to side effects at concentrations higher 6 
than 10 mg/kg edelfosine. Clinical scores for groups of PBS-treated (n=3), 10 mg/kg 7 
edelfosine treated (n=3), 15 mg/kg edelfosine treated (n=2) and 25 mg/kg edelfosine treated 8 
(n=2) EAE mice. Note that the treatment of mice with 25 mg/kg and 15 mg/kg edelfosine led 9 
to drug-related side effects which possibly had an impact on EAE development in immunized 10 
mice that remained clinically inconspicuous. (B) The preventive administration of edelfosine 11 
every other day had no significant effect on RR-EAE clinical scores in immunized SJL mice. 12 
Depicted groups: PBS-treated (n=6), 1 mg/kg edelfosine treated (n=6) and 10 mg/kg 13 
edelfosine treated (n=6) EAE mice. (C) Clinical scores for groups of PBS-treated (n=3), 1 14 
mg/kg edelfosine treated (n=4) and 10 mg/kg edelfosine treated (n=7) EAE mice with 15 
administration starting at disease onset (day 11). A treatment effect could not be proved. EAE 16 
experiments are shown as mean values ± SEM; *P<0.05, **P<0.01 after 2-way ANOVA. (D) 17 
No significant reduction in cumulative disease scores was determined for groups of 18 
immunized SJL mice that were treated every other day beginning at day 5 with 1 mg/kg 19 
edelfosine or 10 mg/kg edelfosine compared to PBS-treated mice. (E) The therapeutic 20 
treatment of EAE-induced SJL mice starting at disease onset (day 11) yielded cumulative 21 
disease scores that implied an edelfosine dose-dependent reduction compared to PBS-treated 22 
controls. However, significance could not be proved. The data that is based on EAE 23 
experiments whose corresponding disease courses are depicted in (B) and (C), respectively, 24 
are shown as mean values ± SEM; *P<0.05, **P<0.01 after post-hoc analysis. 25 
 26 
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Figure 2. Edelfosine application influenced EAE in SJL mice. (A) The preventive treatment 1 
of EAE-induced SJL mice with 10 mg/kg edelfosine on a daily basis ameliorated the disease 2 
course: depiction of clinical scores for groups of PBS-treated (n=7), 1 mg/kg edelfosine 3 
treated (n=7) and 10 mg/kg edelfosine treated (n=7) EAE mice. The EAE experiment is 4 
shown as mean values ± SEM; *P<0.05 after 2-way ANOVA. (B) Cumulative disease scores 5 
were reduced upon preventive edelfosine treatment of EAE-induced SJL mice. The daily 6 
administration of 10 mg/kg edelfosine to EAE-induced SJL mice , but not the administration 7 
of 1 mg/kg edelfosine , reduced the cumulative disease score compared to PBS-treated 8 
controls . The data that is based on EAE experiments whose corresponding disease courses 9 
are depicted in (A) are shown as mean values ± SEM; *P<0.05 after post-hoc analysis. 10 
 11 
Figure 3. Increased frequency of naïve CD4+ T cells after treatment with 10 mg/kg 12 
edelfosine. (A) Lymph node T cells of EAE-induced PBS- or edelfosine-treated SJL mice 13 
were analyzed for frequencies of CD4+ and CD8+ T cell subsets, but also for their expression 14 
of CD62L and CD44 on the cell surface. (B) CD4+ and CD8+ T cell frequencies remained 15 
unchanged irrespective of the treatment. (C) Increased frequencies of CD62L+CD44- naïve 16 
CD4+ T cells were detected in lymph nodes of mice that received 10 mg/kg edelfosine (1.22-17 
fold). Frequencies from one representative of two independent EAE experiments (n=3 for 18 
each group in each experiment), fold-changes merged from two independent EAE 19 
experiments are shown as mean values ± SEM (  PBS,  1 mg/kg edelfosine,  10 20 
mg/kg edelfosine); *P<0.05 after post-hoc analysis. 21 
 22 
Figure 4. Edelfosine treatment induced the upregulation of activated caspase-3. (A) Gating 23 
strategy for activated caspase-3 in CD4+ and CD8+ T cells as well as their activated, CD69+ 24 
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descendants. (B) Representative frequencies of CD4+ and CD8+ T cells as well as activated 1 
CD4+ and CD8+ T cells with activated caspase-3. Here, cells were prepared from lymph 2 
nodes. (C) Treatment of EAE-induced mice with 10 mg/kg edelfosine resulted in a significant 3 
increase in CD4+ and CD8+ T cell frequencies with activated caspase-3 which was also found 4 
for CD8+CD69+ T cells (spleens). Frequencies from one representative of two independent 5 
EAE experiments (n=3 for each group in each experiment), fold-changes merged from two 6 
independent EAE experiments are shown as mean values ± SEM (  PBS,  1 mg/kg 7 
edelfosine,  10 mg/kg edelfosine); *P<0.05 after post-hoc analysis. 8 
 9 
Figure 5. Edelfosine treatment of EAE-induced mice did not compromise proliferation 10 
capacity of lymph node- or spleen-derived cells. (A) After daily treatment of EAE-induced 11 
mice with either PBS or edelfosine, lymph node cells and spleen cells (not shown) were 12 
prepared, restimulated ex vivo with Con A, anti-CD3 antibody or PLP(139-151) and cultured for 13 
72 h (+ stimulus added, - controls, absence of stimulus). Each symbol represents the mean 14 
value of triplicate approaches. Results from one representative of two independent EAE 15 
experiments (n=3 for each group in each experiment). (B) The relative proliferative response 16 
of cells within each condition expressed as SI. Lymph node- as well as spleen-derived cells 17 
showed no significant differences comparing the SIs of cells that were prepared from mice 18 
that received PBS, 1 mg/kg edelfosine or 10 mg/kg edelfosine and challenged with the same 19 
stimulus. Graphs display merged results from two independent experiments (n=6). 20 
 21 
Figure 6. Analysis of edelfosine treatment effects on T cell subsets. (A) The gating strategy 22 
allows to examine CD4+ and CD8+ T cell frequencies as well as CD4+CD25+Foxp3+ nTregs. 23 
Treatment of mice with 10 mg/kg edelfosine resulted in a reduced frequency of CD4+ T cells 24 
in the CNS in the acute phase of EAE compared to treatment with PBS or 1 mg/kg edelfosine. 25 
(B) No differences in the frequency of nTregs were seen in the CNS of mice treated with 10 26 
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mg/kg edelfosine in comparison to PBS-treated mice. Frequencies from one EAE experiment 1 
(n=4 for each group, except PBS-treated group: n=3), frequencies are shown as mean values ± 2 
SEM (  PBS,  1 mg/kg edelfosine,  10 mg/kg edelfosine); *P<0.05, **P<0.01 after 3 
post-hoc analysis. 4 
 5 
Figure 7. Edelfosine treatment affected cytokine production of T lymphocytes. (A) The 6 
production of IFN-γ and IL-17 by CD4+ or CD8+ T cells was analyzed after intracellular 7 
cytokine staining. Dead cells were excluded. (B) The treatment of mice with 10 mg/kg 8 
edelfosine led to a decrease in frequencies of IFN-γ-producing CD8+ T cells compared to 9 
PBS-treated and 1 mg/kg edelfosine-treated mice. For IL-17-producing CD4+ T cells the P-10 
value was 0.0463, but no differences between groups were found in post-hoc analysis. 11 
Frequencies from one EAE experiment (n=4 for each group, except PBS-treated group: n=3), 12 
frequencies are shown as mean values ± SEM (  PBS,  1 mg/kg edelfosine,  10 13 
mg/kg edelfosine); *P<0.05, **P<0.01 after post-hoc analysis. 14 
 15 
Figure 8. Increased caspase-3 activation upon application of edelfosine. (A) CD4, CD8 and 16 
CD69 allowed the investigation of caspase-3 activation induced by edelfosine treatment. (B) 17 
CD4+ T cells with activated caspase-3 showed that treatment with 10 mg/kg edelfosine 18 
increased the frequency of this apoptosis-indicative population compared to respective cells 19 
from PBS-treated mice. Frequencies from one EAE experiment (n=4 for each group, except 20 
PBS-treated group: n=3), frequencies are shown as mean values ± SEM (  PBS,  1 21 
mg/kg edelfosine,  10 mg/kg edelfosine); *P<0.05 after post-hoc analysis. 22 
 23 
Figure 9. Reduction of NeuN+ neurons in the acute phase was prevented by edelfosine. (A) 24 
Immunized SJL mice were treated daily with PBS or edelfosine. CNS was prepared at day 14. 25 
The EAE course revealed a significant treatment effect with differences between PBS-treated 26 
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mice and mice that received either 1 mg/kg or 10 mg/kg edelfosine (day 11 to 13). (B) For 1 
each mouse, six sections of the cervical spinal cord were stained using an anti-NeuN 2 
antibody. Per section two photographs were evaluated for each of the two ventral horns. 3 
NeuN+ neurons were counted to determine means. Compared to non-immunized, age-matched 4 
SJL mice PBS-treated EAE mice showed a reduced number of NeuN+ neurons. This reduction 5 
could be prevented by treatment with either 1 mg/kg or 10 mg/kg edelfosine. (C) 6 
Representative photographs of cervical spinal cord sections stained for NeuN+ neurons after 7 
treatment with either PBS, 1 mg/kg or 10 mg/kg edelfosine (scale bar represents 100 µm, 8 
magnification: 20x). 9 
 10 
Supplementary Figure 1. Analysis of leukocyte subset frequencies. The specific expression 11 
of cell surface markers allowed discrimination between cell types as exemplified by this 12 
gating strategy depicting lymph node cells from an EAE-induced, 10 mg/kg edelfosine-treated 13 
mouse. Frequencies were determined by relating the detected number of events within the 14 
respective gate to the measured number of CD45+ events. 15 
 16 
Supplementary Figure 2. Quantification of immune cell infiltration at the acute phase of 17 
EAE. (A) The acute phase of EAE was accompanied by a maximal clinical impairment of 18 
mouse movement. PBS-treated mice showed the expected development of EAE whereas the 19 
treatment of mice with 1 mg/kg edelfosine or 10 mg/kg edelfosine resulted in milder clinical 20 
EAE scores. In detail, a significant treatment effect was found with significant differences 21 
between PBS-treated and 1 mg/kg edelfosine-treated groups (day 14, 15) as well as between 22 
PBS-treated and 10 mg/kg edelfosine-treated groups (day 13 to 15). (B) Infiltrating CD45+ 23 
immune cells into brains and spinal cords were prepared and quantified by flow cytometry. 24 
(C) Quantification of CNS-infiltrating CD45+ leukocytes was performed by flow cytometry 25 
using BD Trucount tubes according to the displayed gating strategy. CD45+ events were 26 
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related to detected bead events in the Fl-1/Fl-2-defined gate and the absolute number of 1 
infiltrating cells was calculated using the absolute bead number. (D) The treatment with 10 2 
mg/kg edelfosine led to a significant reduction in T cell frequencies compared to PBS 3 
treatment. Frequencies from one EAE experiment (n=4 for each group, except PBS-treated 4 
group: n=3), frequencies are shown as mean values ± SEM (  PBS,  1 mg/kg 5 
edelfosine,  10 mg/kg edelfosine); *P<0.05 after post-hoc analysis.  6 
 7 
Supplementary Figure 3. Identification of infiltrating cells into the CNS of EAE-induced 8 
SJL mice in the acute phase due to the expression of characteristic surface marker molecules. 9 
After the separation of CD45int CNS-residing microglia from CD45high infiltrating leukocytes, 10 
the latter population was further specified (leukocyte subsets) as exemplified by this gating 11 
strategy depicting cells from an EAE-induced, 10 mg/kg edelfosine-treated mouse. 12 
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